P ulmonary artery (PA) hypertension (PAH) is a severe and progressive condition characterized by increased mean pulmonary arterial pressure >25 mm Hg at rest, with a normal PA wedge pressure in the absence of chronic respiratory, cardiac, or thromboembolic disease.
endothelial-to-mesenchymal transition, endothelial and pulmonary arterial smooth muscle cell (PASMC) proliferation, pulmonary vasoconstriction, and inflammation. The nature of the initial trigger that promotes pulmonary vascular cell proliferation is still unclear. During the last decade, genetic studies have identified several predisposing genes associated with PAH, mainly within the transforming growth factor-β signaling pathway. 2 
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Recently, using whole-exome sequencing, Ma and colleagues 3 identified KCNK3 (which codes for the potassium channel subfamily K member 3) as a new predisposing gene for PAH. KCNK3 mutations were identified in 2 of 92 unrelated patients (3.2%) with familial PAH and in 3 of 230 patients (1.3%) with sporadic PAH. PAH caused by a KCNK3 mutation is an autosomal-dominant disease with incomplete penetrance, as has been previously described for BMPR2 mutations. A KCNK3 mutation causes the first channelopathy identified in PAH. 4 The KCNK3 gene encodes for an outward K + channel characterized by the presence of 4 transmembrane domains and 2 pore domains per subunit 5 and is a member of 2-poredomain K + channels (K2P). KCNK3, also called Twik-related acid-sensitive K + channel (TASK1), shares several characteristics with the background K + current, including minimal voltage sensitivity, extracellular pH sensitivity, resistance to classic K + channel inhibitors, and insensitivity to cytoplasmic Ca 2+ . 6 Electrophysiological experiments have demonstrated a loss of function in all identified mutations of the channel. 3 However, additional experiments are required to decipher the pathophysiological role of KCNK3 channels in the development of nonheritable forms of PAH.
In the present study, we investigated the expression and function of KCNK3 in patients with idiopathic PAH (iPAH) and heritable PAH (hPAH) who do not carry PAH-causing mutations by assessing the associated biochemical and molecular biology. We also evaluated the role of KCNK3 in the development of pulmonary hypertension (PH) using the wellestablished PH rat model induced by monocrotaline exposure (MCT-PH). We measured the involvement of KCNK3 in pulmonary arterial tone using organ bath studies. We analyzed the consequences of long-term in vivo inhibition of KCNK3 in rats using a selective KCNK3 channel blocker (ie, A293, Sanofi, France) at the pulmonary vascular level.
Our overall hypothesis is that loss of function of KCNK3 is a hallmark for all forms of PH and contributes to PASMC and PAEC dysfunction and that stimulating KCNK3 function in vivo with ONO-RS-082 3 could alleviate experimental PH.
Methods
The online-only Data Supplement provides further details of our methods, including the suppliers and chemicals used.
Patients
Human lung specimens were obtained at the time of lung transplantation from 11 patients with PAH and at the time of a lobectomy or pneumonectomy for localized lung cancer from 12 control subjects. PAH patients underwent genetic counseling and gave their written informed consent for genetic analysis. Five patients with PAH were carriers of BMPR2 mutations (p.Arg321X, p.Arg491Trp, p.Tyr113X, deletion of exon 3, and a splice defect in intron 3: c.418+3A>T) and corresponded to hPAH. No BMPR2 mutations were identified in 6 patients, who were also included in the genome-wide association study analysis of Ma and collaborators, 3 and were not carriers of a KCNK3 mutation. These patients corresponded to iPAH. In the lung specimens from control subjects, pulmonary arteries were studied at a distance from tumor areas. Transthoracic echocardiography was performed preoperatively in control subjects to rule out PH. The patients studied were part of the French Network on Pulmonary Hypertension, a program approved by our institutional Ethics Committee, who had given their written informed consent (protocol N8CO-08-003, ID RCB: 2008-A00485-50, approved June 18, 2008) .
Materials
Tetraethylammonium, glibenclamide, Bay-K8644, papain, dithiothreitol, and monocrotaline were obtained from Sigma. ONO-RS-082 was obtained from Enzolife Sciences. U44619 was purchased from Interchim. The selective blocker of KCNK3, A293 (2-(butane-1-sulfonyl-amino)-N-[1-(R)-(6-methoxypyridin-3-yl)-propyl]-benzamide, was kindly provided by Sanofi-Aventis. 7 
Hemodynamic Measurements, Evaluation of Right Ventricular Hypertrophy, and Tissue Collection
Rats were anesthetized with isoflurane (Minerve, Esternay, France). Hemodynamic measurements were recorded as previously described. 8 For the Fulton index of right ventricular (RV) hypertrophy, the ratio of RV weight to left ventricular plus septum weight was calculated.
Isolation of PASMCs
Hearts and lungs were rapidly excised into ice-cold physiological Ca 2+ -free Hanks media. First-to third-order intrapulmonary arteries, with diameters between 2 and 0.2 mm, were dissected; the endothelium of vessels was disrupted by rubbing the luminal surface with a cotton swab; the fibroblast-containing adventitial layer was removed; and the media containing PASMC was dissociated with a cocktail containing papain, dithiothreitol, and BSA, as previously described by Hong et al.
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Isolation of PAECs
After dissection of the pulmonary arteries, PAECs were enzymatically dissociated according to an adapted protocol previously described by Paffett et al.
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Electrophysiological Recordings K + currents were recorded with the whole-cell patch-clamp technique at room temperature (22°C -24°C) in normoxic conditions with an Axopatch 200B amplifier, a Digidata 1440A, and pClamp 10 software (Molecular Devices, Sunnyvale, CA). Borosilicate glass pipettes (Harvard Apparatus) were pulled with a Sutter puller and fire polished; they had a resistance of 3 to 5 MegaΩ. The pipette solution contained (in mmol/L) 130 KCl, 1 MgCl 2 , 10 HEPES, and 1 EGTA, pH 7.2 (adjusted with KOH). The bath solution contained (in mmol/L) 124 NaCl, 5 KCl, 0.5 NaH 2 PO 4 , 0.5 KH 2 PO 4 , 1 MgCl 2 , 1 CaCl 2 , 10 HEPES, and 10 glucose, pH 7.4 (adjusted with NaOH). Cell capacitances (9-15 pF for PASMCs and 4-5 pF for PAECs) were obtained for each cell measured, and the current was normalized to the cell capacitance.
The cell was clamped at 0 mV for 3 minutes, allowing I Kv inactivation. The residual steady-state current was measured as the noninactivating current, I KN . The KCNK3 current was recorded by applying a 1.2-second voltage ramp from 60 mV to -100 mV. I KV was elicited by applying a 400-millisecond voltage step to 0 mV from a holding potential of -40 mV. Then, we applied A293 (KCNK3 inhibitor) and measured the A293-sensitive current corresponding to I KCNK3 . Resting membrane potentials (E m ) were assessed with the current clamp (I=0) mode. The junction potential of ≈4.6 mV between the pipette and bath solution was corrected offline. intrapulmonary arterial segments (length, 1.4-2 mm) were mounted on the jaws of the myograph using a 25-μm-diameter tungsten wire. Data acquisition was performed with PowerLab 8/30 and LabChart Pro version 7.1 software (AD Instrument). The protocols are detailed in the online-only Data Supplement.
Quantitative Polymerase Chain Reaction
Total RNA was extracted with the classic Trizol procedure. One μg total RNA was reverse-transcribed with a QuantiTect Reverse Transcription Kit (Qiagen). For gene expression quantification, we used Applied Biosystems TaqMan gene expression assays with the TaqMan Universal PCR Master Mix. The results were analyzed using the 2 −ΔΔCT method. The primers used in this study are listed in Table I in the online-only Data Supplement.
Multiplex Data
We performed simultaneous quantification of recognized serum biomarkers of cardiovascular diseases in sera from rats using the Millipore Milliplex (RV1MAG-26K and RV2MAG-26K, Millipore, Molsheim, France). Data were analyzed with Bioplex manager software, version 6.1 (Biorad), at Plate-forme Cardiex-Therassay (University of Nantes, Nantes, France).
Western Blot Analysis
Human or rat lung tissue samples were prepared as previously described. 12 The Western blot protocol is described in the online-only Data Supplement.
Immunofluorescence Staining
Frozen lungs were prepared as previously described. 13 Immunofluorescence labeling is described in the online-only Data Supplement.
Statistical Analyses
Data are expressed as the mean±SEM of n observations. Comparisons were made with the Mann-Whitney (comparison between 2 groups) or Kruskal-Wallis test (comparison between >2 groups). Differences were considered statistically significant at P<0.05. All statistical tests were performed with GraphPad Prism software (GraphPad, version 6.0 for Windows).
Results
KCNK3 Is Functionally Expressed in Freshly Isolated (Noncultured) PASMCs From Control Rats
Multiple immunofluorescence labeling revealed that KCNK3 was expressed in situ in PASMCs and PAECs ( Figure 1A ) and was maintained in freshly isolated PASMCs from control rats ( Figure 1B) .
Whole-cell patch-clamp experiments to measure endogenous KCNK3 current in isolated rat PASMCs showed that the KCNK3 channel was insensitive to standard K + channel blockers (tetraethylammonium and glibenclamide). 14 PASMCs were clamped at 0 mV for 3 minutes to inactivate the voltage-dependent K + channels (Kv). We then applied a voltage ramp protocol between 60 and -100 mV for 100 milliseconds, as shown in Figure 1C . Residual Kv and KATP channels were inhibited by simultaneous applications of tetraethylammonium (10 mmol/L, general K + channel blockers) and glibenclamide (10 μmol/L, K ATP channel blocker). In agreement with the KCNK3 channel properties, 15 the K + current was blocked by decreasing external pH to 6.3, whereas an external pH of 8.3 highly increased the current. This effect was reversed by returning to the external solution pH to 7.3 ( Figure 1C and 1D ).
KCNK3 Current and KCNK3 Expression Decreased Progressively During the Development of PH
MCT-PH is the standard model for severe PH. The progressive neomuscularization and obstruction of precapillary resistance in arteries that occurred in the MCT-PH rat model led to a delayed and progressive increase in mean pulmonary arterial pressure and RV hypertrophy, as measured by the Fulton index, developing 14 days after monocrotaline exposure and becoming established and severe by day 21 (Figure 2A and 2B) .
To discriminate the KCNK3 current, we measured the difference in K + current at external pH values of 8.3 and 6.3. We named this current the acidic-K + -sensitive current. Our results showed a progressive decrease in the acidic-K + -sensitive current with the change in PH (ie, at 7, 14, and 21 days after exposing Wistar rats to monocrotaline). At 7 days after exposure to MCT, the acidic-K + -sensitive current was significantly reduced by 30%; it was reduced by 80% at 14 days and by 90% at 21 days ( Figure 2C and 2D) .
Expression of lung KCNK3 protein was reduced by 80% to 90% at 14 and 21 days after monocrotaline exposure ( Figure 2E and 2F). However, it was not affected at 7 days even though the acidic current was already significantly reduced at this early time point. Moreover, transcription of KCNK3 was also impaired by 80% in isolated PAs (not shown), whereas the KCNK3 mRNA level was normal in pulmonary veins (not shown).
Using the current clamp mode, we measured significant and progressive depolarization of the resting membrane potential (Em). Em values were -35±1.52, -26±4.0,-20±1.1, and -21.6±2.6 mV in the controls at 7, 14, and 21 days after monocrotaline exposure, respectively ( Figure 2G ).
Decreased KCNK3 function/expression was also observed in another strain of rats, Sprague-Dawley rats. In SpragueDawley rats, the acidic-K + -sensitive current was reduced by 62% and 85% at 7 and 21 days, respectively, after monocrotaline exposure ( Figure 2H ). KCNK3 protein level was also reduced by 90% in Sprague-Dawley rats after monocrotaline exposure ( Figure 2I) . Surprisingly, the acidic-K + -sensitive current was 2-fold higher in PASMCs from Sprague-Dawley rats compared with Wistar rats, which could be explained by the differential expression of TASK2, another pH-sensitive channel ( Figure I in the online-only Data Supplement).
Moreover, we confirmed (by immunostaining) the plasma-membrane localization of KCNK3 in freshly isolated PAECs. Isolated PAECs were positive for the EC marker CD31 (Figure 2J ), positive for von Willebrand factor, and negative for α-smooth-muscle actin (not shown). To measure KCNK3 current specifically in isolated PAECs, we previously labeled ECs with a Dylight 594-conjugated tomato lectin from Lycopersicon esculentum (a specific marker for EC). At 7 days after monocrotaline exposure, the acidic-K + -sensitive current was reduced by 80% ( Figure 2K ) and was associated with membrane depolarization (-26.6±1.38 mV in controls versus -18.7±2.8 mV after monocrotaline exposure; Figure 2L ).
Correlative electron microscopy experiments performed on controls or MCT-PH lung samples from rats nicely However, we also measured a strong reduction in the intensity of other K + currents and a decrease in mRNA level of Kv1.2, Kv2.1, Kv1.4, Kv4.2, and Kv4.3 in severe MCT-PH, whereas other K2P channels (TASK2, TWIK1) were not affected ( Figure IIIA -IIIC in the online-only Data Supplement).
A293 Inhibits Endogenous KCNK3 Current in Freshly Isolated PASMCs and Modulates the Vascular Tone of the PA
External acidic pH is known to inhibit other members of the K2P family. 16 To characterize I KCNK3 more specifically, we used a selective KCNK3 blocker: A293 (supplied by Sanofi). The dose response of A293 on global K + current caused a maximal decrease in global K + current at 1 μmol/L ( Figure IVA in the online-only Data Supplement). To minimize any nonspecific effects, we also used A293 at 200 nmol/L. At 200 nmol/L, A293 reduced K + current by 30% ( Figure IVA and IVB in the online-only Data Supplement). As expected, in MCT-PH, the A293-sensitive current was reduced by 90% in PASMCs ( Figure 3A ). In the presence of tetraethylammonium (TEA) plus glibenclamide (Glib), A293 reduced K + current similarly to acidic pH ( Figure 3B and Figure IVA-IVC) , thus confirming the ability of A293 to inhibit KCNK3. Using this specific pharmacological approach, we confirmed that KCNK3 function was severely reduced in PASMCs from MCT-PH rats and that KCNK3 was involved in the maintenance of resting Em (-40 to -30 mV; Figure 3C ).
Using isolated vessels in organ bath experiments, we assessed the involvement of KCNK3 in controlling rat pulmonary arterial tone. We hypothesized that if KCNK3 significantly contributed to the resting tone of PA, then one would Figure 3E and 3F). Used at 200 nmol/L, A293 also induced significant contraction of Bay-K8644-prestimulated PAs (8%-10% of the K80 response) and shifted the concentrationeffect curve to the left compared with vehicle ( Figure IVD and IVE in the online-only Data Supplement). Additionally, in the presence of A293, the addition of 10 mmol/L tetraethylammonium, known to block other K + channels, including BK Ca and some Kv, 14 evoked significant PA constriction (20% of the K80 response; Figure 3G ). Finally, 1 μmol/L A293 significantly potentiated the contractile response of the thromboxane A 2 mimetic U46619, shifting the concentration-effect curve to the left compared with vehicle ( Figure 3H and 3I ). Taken together, these results demonstrate that KCNK3 inhibition with 1 μmol/L A293 predisposes PAs to constrict.
Pulmonary Expression of KCNK3 Is Reduced in Patients With PAH
We analyzed the pulmonary expression of KCNK3 in mRNA (isolated PA) and protein (lung tissues) from patients with iPAH and control subjects ( Figure 4A and 4B ). As shown in Figure 4 , protein (n=4) and mRNA (n=5) levels of KCNK3 were significantly reduced in patients with iPAH compared with the control subjects (P<0.05; Figure 4A and 4B). Using patch-clamp technique, we then evaluated KCNK3 function in cultured human PASMCs (control and iPAH) plus the selective KCNK3 blocker A293 at 200 nmol/L. In iPAH PASMCs, the A293-sensitive current was reduced by 80% compared with non-PAH human PASMCs ( Figure 4C and 4D) . We showed that lung protein expression of KCNK3 was significantly reduced in patients with hPAH carrying a BMPR2 mutation (n=5; Figure 4E ). Pulmonary expression of potassium channel subfamily K member 3 (KCNK3) is reduced in patients with pulmonary arterial (PA) hypertension (PAH). A, Representative Western blot image to quantify KCNK3 expression in the lungs from control and patients with idiopathic PAH (iPAH; n=4). β-Actin was used as a loading control. Right, Mean values of A (n=4 for control subjects and patients with PAH). B, mRNA level expression of KCNK3 on PAs isolated from control subjects and patients with iPAH (n=4 for both control subjects and patients with PAH). C, Current-voltage relationship of the A293-sensitive current in human control and iPAH PA smooth muscle cells. Right, Quantification of the A293-sensitive current (n=10 and 7 cells). E, Representative Western blot image to quantify KCNK3 expression in lungs from control subjects (n=6 patients), patients with heritable PAH (hPAH) who were carriers of a BMPR2 mutation (n=5 patients). β-Actin was used as a loading control. Figure 5A) . Interestingly, the A293-sensitive current was strongly reduced after 7 and 28 days of A293 exposure (no significant differences were measured between 7 and 28 days; Figure 5B and 5C). Moreover, PASMCs isolated from A293-treated rats were significantly depolarized (-40 to -31 mV; not shown), whereas mRNA expression and protein expression of KCNK3 were not modified ( Figure 5D-5F ).
To evaluate the consequence of KCNK3 inhibition on in situ pulmonary cell proliferation, we visualized cells undergoing DNA replication in A293-exposed rats by measuring the incorporation of 5-ethynyl-2'-deoxyuridine (EdU; yellow arrows in Figure 5 ). As expected, we detected very few EdU-positive cells in control lung parenchyma ( Figure 5G ), whereas there were areas of intense microvascular EC proliferation (CD34 Figure 5Gc ). 18 To ascertain the overproliferation of adventitial fibroblasts in A293-treated rats, we performed coimmunostaining with the fibroblast markers CD90 and fibronectin. As shown in Figure V Interestingly, some EdU-positive cells were CD4 + (T-helper cell markers) or CD8 + (cytotoxic T-cell markers), denoting the presence of active inflammation in A293-exposed rats ( Figure  VIA and VIB in the online-only Data Supplement). Moreover, in rats treated for 7 days, the number of proliferative cells was significantly increased compared with controls but was still 2-fold less than in rats treated for 28 days (Figure 5Gd) . Accordingly, A293-treated rats presented with significant distal neomuscularization ( Figure 5H ). Interestingly, A293-treated rats displayed significantly increased right ventricular systolic pressure ( Figure 5I ), whereas the RV was not yet hypertrophied (not shown) and cardiac output was not altered ( Figure 5I ).
Western blot analysis demonstrated increased expression of the fibroblast markers vimentin and phosphorylated vimentin (Ser55) in the lungs from A293-exposed rats (28 days) compared with control rats ( Figure 6A ). We also observed significantly increased phosphorylation of ERK1/2 in the lungs of A293-exposed rats (proliferative pathway; Figure 6A ). At 28 days (but not 7 days), long-term KCNK3 inhibition led to significantly increased mRNA levels of platelet-derived growth factor (PDGF) receptor b, PDGFa, interleukin (IL)-17Ra, and α1 antitrypsin (A1AT; Figure 6B and 6C) .
Moreover, the serum levels of monocyte chemoattractant protein-1 (MCP-1), tissue inhibitor of metalloproteinase-1 (TIMP-1), and Gro-1 (melanoma growth stimulating activity, alpha 1) were significantly higher in A293-treated rats compared with vehicle-treated rats ( Figure 6D and 6E ). This was related to an increase in lung mRNA expression of MCP-1, TIMP-1, and Gro-1. Other markers of endothelial dysfunction and inflammation were not modified (caveolin-1, CTGF, Interleukin 6, plasminogen activator inhibitor-1, tumor necrosis factor-α, adiponectin, soluble E-selectin, soluble intracellular adhesion molecule-1, von Willebrand factor; not shown). Kv1.5 mRNA expression was significantly reduced in A293-exposed rats (28 days), whereas Kv2.1 mRNA expression was not affected ( Figure 6F ).
In Vivo Pharmacological Activation of KCNK3 Interferes With MCT-PH Development
Because we had demonstrated that KCNK3 is downregulated in the lungs and PA of patients with PAH and MCT-PH rats, we next evaluated the consequences of in vivo pharmacological activation of the KCNK3 channel using ONO-RS-082. In 2007, a patent explored the molecules associated with phosphorylation of the human KCNK3 channel. The authors of the patent found several molecules that could modulate human KCNK3, including the phospholipase A2 inhibitor ONO-RS-082. 18a In their work, which identified KCNK3 mutations in PAH, Ma and colleagues 3 proposed that ONO-RS-082 could be a beneficial therapeutic approach to target KCNK3.
In vitro, we demonstrated, using the patch-clamp technique, that ONO-RS-082 (10 μmol/L) improved KCNK3 current (tetraethylammonium-insensitive current; Figure VIIA and VIIB in the online-only Data Supplement). However, when administrated in vivo from days 14 to 21 to MCT-PH rats, ONO-RS-082 was inefficient at alleviating PH in MCT-PH rats ( Figure VIIC in the online-only Data Supplement). Of relevance, we demonstrated that KCNK3 expression was totally abolished at these time points (Figure 2) . Hence, we used a long-term treatment of ONO-RS-082 at 50 mg·kg −1 ·d −1 (from days 1-21; Figure 7A ). At 3 weeks after treatment initiation, the hemodynamic measurements demonstrated that the longterm application of ONO-RS-082 significantly reduced PH induced by exposure to MCT. Compared with MCT-vehicle rats, a 50% reduction in RV systolic pressure ( Figure 7B ) and a 60% reduction in RV hypertrophy ( Figure 7C ) were observed in ONO-RS-082 rats receiving monocrotaline, whereas cardiac output was not improved by the ONO-RS-082 treatment ( Figure 7D ). Additionally, long-term administration of ONO-RS-082 induced a significant reduction in vascular wall thickness compared with MCT-vehicle rats ( Figure 7E and 7F). Moreover, in the monocrotaline ONO-RS-082 group, Western blot analysis demonstrated lung KCNK3 expression similar to that in the control group ( Figure 7G ). These results demonstrate the potential efficacy and pharmacological therapeutic action on KCNK3 function to reduce PH when KCNK3 expression is still present.
Discussion
This study has 5 major findings. Using a combination of patch-clamp recording methods and biochemical and ex vivo and in vivo approaches, we have provided, for the first time, strong evidence for the following. First, KCNK3 expression and function are severely reduced in iPAH, hPAH, and MCT-PH. Second, I KCNK3 current decreases progressively during the development of MCT-induced PH and was correlated with the depolarization of the resting plasma membrane. Third, KCNK3 modulates pulmonary arterial tone. Fourth, long-term inhibition of KCNK3 (with the compound A293) enhances distal artery neomuscularization, together with subsequent development of early hemodynamic signs of PH, and exacerbated proliferation of PAECs, PASMCs, and adventitial fibroblasts, in association with an increase in some markers of inflammation. Fifth, in vivo pharmacological activation of KCNK3 reduces the development of PH in the monocrotaline rat model. Interestingly, we have shown that reduction in KCNK3 expression and function are concomitant to PH induction and precedes hemodynamic changes, thus suggesting that reduction of I KCNK3 is not a mere consequence of PH but rather an active player in its pathogenesis. At 1 week after PH initiation, I KCNK3 is reduced, whereas protein expression of KCNK3 is as yet unaffected, suggesting that KCNK3 may be not correctly addressed to the plasma membrane or inhibited. Correlated to the decrease of I KCNK3 , the plasma membranes of PASMCs and PAECs from MCT-PH rats are depolarized by ≈10 mV, confirming the role of KCNK3 in resting Em, which has been previously suggested as a nonspecific KCNK3 inhibitor (acidic pH or anandamide) 15 or an siRNA strategy. 19 In this study, we used a selective KCNK3 inhibitor (A293), which was originally described to inhibit 90% of KCNK3 current, 50% percent of KCNK9 current, and <10% of other K + channels tested (TASK2, TASK4, TREK-1, Kv1.1, Kv1.3, Kv1.4, Kv1.5, Kv4.3, and hERG) at 1 μmol/L. 7 Of note, KCNK9 is not expressed in rat PA 15 (data not shown) and hence cannot be part of the K + current. In line with the role played by KCNK3 in resting Em, we have demonstrated that KCNK3 inhibition modulates pulmonary arterial tone and contributes to vasoconstriction.
Manoury and coworkers 20 suggested a crucial role for KNCK3 function in PASMCs, which we have highlighted in our study. They demonstrated that KCNK3 is almost lost in culture conditions (a highly proliferative phenotype) compared with in situ conditions (contractile condition). In line with this observation, patch-clamp measurements of human cultured PASMCs revealed that the A293-sensitive current was smaller than the current recorded on PASMCs freshly isolated from rats (by 10-fold). Moreover, the A293-sensitive current was significantly reduced in human iPAH PASMCs compared with controls. Hence, in our study, we mainly used freshly isolated PASMCs or PAECs.
It is well established that the MCT-PH model is characterized by abnormal pulmonary vascular cell proliferation. In vivo long-term KCNK3 inhibition experiments have revealed an exaggerated proliferation of PAECs, PASMCs, and adventitial fibroblasts, which are hallmarks of PAH, 21 further demonstrating the role of KCNK3 in the loss of function and as an initial molecular trigger of PAH by promoting cell proliferation. Accordingly, knockdown of KCNK3 in mouse neuroblastoma N2A cells increases N2A cell proliferation rates by >25%, 22 thus illustrating our finding. At a mechanistic level, long-term inhibition of KCNK3 induced increased expression of A1AT, which could participate in the hyperproliferative phenotype of adventitial fibroblasts. Indeed, high levels of A1AT are, for instance, observed in lung adenocarcinoma cell line, 23 and A1AT stimulates fibroblast proliferation in vitro 24 ; conversely, decreased expression of A1AT reduces cell migration and cell invasion. 23 Moreover, the vimentin overexpression observed in A293-treated lungs suggests the accumulation of pulmonary fibroblasts. Like A1AT, vimentin is a cancer marker involved in cell proliferation and migration processes 25 and in mesenchymal transition, which could potentially occur during the development of vascular pathologies. 26 We have recently demonstrated high expression of vimentin and of phosphorylated vimentin (Ser55) during the development of PAH. 13 Ser55 on vimentin is phosphorylated in various types of cells only during the early mitotic phase by Cdk1. 27 Vimentin has been shown to interact with phosphorylated extracellular signal-regulated kinase (ERK) 1/2 and to protect it against dephosphorylation, extending its mitotic potential. Accordingly, we observed increased phosphorylation of ERK1/2, which certainly supports vascular proliferation induced by the inhibition of KCNK3. Our results also suggest that PA remodeling, induced by KCNK3 inhibition, may occur though the PDGF/PDGF receptor axis, a crucial promitotic axis in PAH. 29, 30 We also observed an increase in MCP-1, TIMP-1, IL-17RA, and other inflammatory molecules known to be implicated in the immunopathology of PAH. 31 This highlights the fact that KCNK3 inhibition acts on the whole spectrum of PAH pathomechanisms, from vasoconstriction and vascular cell proliferation to PAH-associated chronic inflammation. For instance and in accordance with our results, (1) TIMP-1 is overexpressed by cultured PASMCs from patients with iPAH, 32 and in vivo TIMP-1 gene transfer occurs in ratpotentialized PAH induced by chronic hypoxia 33 ; (2) MCP-1/ CCL2 is strongly involved in the development of human and experimental PAH 34, 35 and plays a key role in arterial remodeling though direct mitotic/chemotactic effects on PASMCs and PAECs but also recruits monocytes/mononuclear cells and populations of circulating progenitors 36, 37 ; and (3) there is an IL-17-dependent (Th17) immune polarization in PAH 38 and IL-17 mRNA, and protein expression is significantly increased in hypoxia-induced PH mouse models. 39 Interestingly, IL-17 binds to its receptor composed of IL-17RA and IL-17RC subtypes, leading to activation of the canonical ERK1/2, phosphoinositide 3-kinase-Akt, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase pathways. 40 We have shown that KCNK3 expression was reduced in patients with iPAH and hPAH and in MCT-PH rats. Interestingly, we have also previously demonstrated that PH induced by cyclophosphamide in rats is associated with a 70% reduction in KCNK3 expression. 12 Moreover, acute hypoxia blocks KCNK3 current in cultured PASMCs. 19 Together, these findings suggest that inhibition of KCNK3 is involved in the development of diverse causes of PH. Indeed, KCNK3 is known to be regulated by several mechanisms involved in PH pathobiology. For instance, endothelin-1, an extremely powerful vasoconstrictor that is involved in vascular remodeling, has been shown to inhibit KCNK3 via Rho kinase in human PASMCs. [41] [42] Growth factor signaling, such as PDGF receptor and tyrosine kinase activity, act via a common pathway that influences the function and expression of K + channels [43] [44] and could also partially explain the decrease in I KCNK3 . Moreover, downstream of the PDGF or tyrosine kinase receptors, Src kinase signaling is crucial for K + channel function, including TASK1/KCNK3. 45 Our findings are summarized in Figure 8 . We propose that the loss of function of KCNK3 is followed by the following sequence of events: (1) plasma-membrane depolarization; (2) PA vasoconstriction; (3) increase in pulmonary vascular cell proliferation (vascular ECs and PASMCs); (4) increase in adventitial fibroblast proliferation via upregulation of phosphorylated ERK1, PDGF, and vimentin; (5) pulmonary inflammation via upregulation of the MCP-1, Gro-1, IL-17 axes; and (6) increase in right systolic ventricular pressure
Limitations
ONO-RS-082 is a phospholipase A2 inhibitor. The impact of ONO-RS-082 treatment on phospholipase A2 activity could also have contributed to alleviate MCT-PH. We have demonstrated here that KCNK3 expression was abolished whereas expression of phospholipase A2 was known to be upregulated in the MCT-PH models (more precisely, 3 and 4 weeks after PH initiation by monocrotaline exposure). 46 If the improvement in PH by ONO-RS-082 was caused by decreased phospholipase A2 activity, we would have observed a partial correction of PH as a curative strategy. This was not the case, suggesting that the improvement in PH by long-term ONO-RS-082 treatment was caused mainly by its pharmacological activation of KCNK3 channels.
Conclusions
In conclusion, we show, for the first time, several lines of evidence that KCNK3 channel dysfunction participates in the development of PH and may act as one of its triggers. As recently supported by the discovery of KCNK3 mutations that cause hPAH, we show that decreased KCNK3 expression is an emerging hallmark of PAH. Lastly, and as suggested by Ma and collaborators, 3 we show that in vivo KCNK3 activation with ONO-RS-082 is viable and effective at restoring/ameliorating PH in our monocrotaline experimental PH model when KCNK3 is expressed. 
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CLINICAL PERSPECTIVE
Pulmonary arterial hypertension (PAH) is a severe cardiopulmonary condition leading to right-sided heart failure and ultimately death. In the last 20 years, the development of drugs that specifically target pathways involved in disease pathogenesis has led to improvements in the quality of life and clinical outcomes in patients with PAH, but there is still no cure for this devastating disease. Recently, the identification of loss-of-function mutations in the gene encoding the potassium channel subfamily K member 3 (KCNK3) in some patients with PAH has highlighted a novel dysfunctional pathway and a potential therapeutic target. In the present study, we demonstrate that loss of function of KCNK3 is a hallmark of idiopathic and heritable PAH and experimental pulmonary hypertension. Moreover, we show that in vivo pharmacological activation of KCNK3 with the phospholipase A2 inhibitor ONO-RS-082 alleviates monocrotaline-induced pulmonary hypertension in rats when KCNK3 is still expressed in pulmonary arteries. This suggests that this strategy might be of interest in patients with PAH who retain a residual level of KCNK3 expression, possibly within the frame of personalized therapy. A major limitation of the ONO-RS-082 compound is its phospholipase A2 inhibitory activity, which can have deleterious side effects. Identification or development of more specific molecules is thus needed to envision KCNK3 activation in humans. Alternatively, targeted gene therapy allowing KCNK3 re-expression in affected pulmonary arteries could be another possible approach.
Supplemental data
Materials and methods
Animal models
Rats were housed at the Faculty of Pharmacy of Châtenay-Malabry (ANIMEX platform, Châtenay MCT-exposed Wistar rats were treated with ONO-RS-082 (50 mg/kg/day in DMSO, daily intraperitoneal injection) from days 14 to 21 in a short and late protocol, and from days 1 to day 21 with a chronic protocol. Control animals received the same volume of DMSO.
In an induction protocol, Wistar rats were exposed daily during one month to the selective KCNK3 blocker, A293. The A293 (10 mg/kg, i.p.) was dissolved in DMSO, as described by the manufacturer.
Control animals received the same volume of DMSO.
Isolation of pulmonary artery smooth-muscle cells (PASMCs)
Hearts and lungs were rapidly excised into ice-cold physiological Ca 2+ -free Hank's solution containing (in mM): 140 NaCl, 4.2 KCl, 1 MgCl2, 1.2 KH2PO4, 10 Hepes, and 0.1 EGTA, 10 Glucose, at pH 7.4 (NaOH). First-to third-order intrapulmonary arteries with diameters of 2-0.2 mm were dissected and kept at 4°C for 10 min in Hank's buffer. Vessel endothelium was disrupted by rubbing the luminal surface with a cotton swab; the fibroblast-containing adventitial layer was removed, and the PASMCcontaining media was dissociated with a cocktail containing papain, DTT, and BSA. Briefly, the vessels were maintained at 4°C for 30 min in Hank's solution (without EGTA), containing papain (1 mg/mL), DTT (0.85 mg/mL), and BSA (0.75 mg/mL), and then at 37°C for 13 min. The arteries were finally washed with Hank's solution (without EGTA) supplemented with 1 mg/mL of glucose and isolated PASMCs were obtained by gentle pipetting. The external calcium concentration was progressively increased and isolated cells were plated in gelatin-coated petri dishes.
Isolation of pulmonary artery endothelial cells (PAECs)
Briefly, pulmonary arteries were treated with 0.2 mg/mL of DTT and 0.2 mg/mL of papain in HBSS for 
Isometric tension measurement
Briefly, second-order IPA segments (length: 1.4-2 mm) were mounted on the jaws of a myograph using a 25-µm tungsten wire. The tissues were bathed in Krebs-Henseleet (KH) solution containing (in mM): NaCl 119, KCl 4.7, CaCl2 2.5, MgSO4 1.17, KH2PO4 1.18, NaHCO3 25, and glucose 11, at 37°C and continuously aerated with a mixture of CO2 and O2 (5%/95%). Each vessel was then submitted to a normalization procedure 13 . Afterwards, the internal circumference of the vessels was set to 90% of the circumference that the vessels would have in situ if held with a transmural pressure of 30 mmHg. Vessels were allowed to equilibrate for 40-60 min. Vessels were then contracted with a solution containing 80 mM of K + (K80). Its composition was otherwise similar to the KH solution except that NaCl that was exchanged on an equimolar basis for KCl. After 10 min, the vessels were washed with KH solution for 30 min and a challenge with K80 was repeated. The contractile responses were expressed as a percentage of the response to the second K80 challenge.
Multiplex data
We performed simultaneous quantification of recognized serum biomarkers of cardiovascular diseases in sera from control and A293-treated rats with Millipore's Milliplex (Millipore, Molsheim, France).
The 
Transmission electron microscopy (TEM) and correlative light and electron microscopy (CLEM)
To determine the ultrastructural localization of KCNK3, correlative light and electron microscopy (CLEM) was used after immuno-labeling. This approach allowed pre-selection of areas with features of interest for detailed ultrastructural study by TEM. Samples of human lung specimens (~2 cm 3 ) were embedded and frozen after fixation in 4% paraformaldehyde and immersed in 10% and then 40% sucrose solutions. Indirect immunofluorescence was performed on frozen sections (10 µm) collected 
